HI
ITCI

Harbour Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Harbour Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed – – 3785
2021
Q3 		$0 Hold
1
– – ﹤0.01% 4051
2021
Q2 		$0 Hold
1
– – ﹤0.01% 4016
2021
Q1 		$0 Buy
+1
New +$35 ﹤0.01% 3750

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Harbour Investments's ITCI Position: Q4 2021 in Review

Harbour Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2021, closing a stake of 1 share.

Harbour Investments first reported a position in ITCI in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 208 funds tracked by Wall St. Rank hold ITCI as of Q4 2021.

  • Harbour Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 1 Intra-Cellular Therapies Inc. share in Q4 2021.
  • Harbour Investments first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Intra-Cellular Therapies Inc. position peaked at $0 in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.